Skip to main content
. 2017 Jun 20;6(7):1541–1551. doi: 10.1002/cam4.1098

Figure 1.

Figure 1

Year when natalizumab‐associated melanoma cases from the United States (US) and other countries (Non US cases) were reported to the Food and Drug Administration. Data source: FDA’s Adverse Event Reporting System (FAERS) database (January 1, 2008‐ March 31, 2014).